Juliet: The purpose of this study is to monitor all patients exposed to CAR-T therapies for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events, monitor for replication competent lentivirus and assess long-term efficacyLong Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy

Trial purpose

Long-term follow-up

Tumor type

Multi-Cancer

Trial acronym

Juliet

Summary

Participants are enrolled following completion or early discontinuation from a Novartis sponsored or supported study of CAR T-cell treatment. 

No treatment will be given in this study.

Participants will be followed for 15 years post-treatment from the last treatment. They will be monitored for safety and efficacy within the primary treatment protocols for the protocol defined duration. Participants can drop off treatment protocols at any time to enter this long-term follow-up (LTFU) study. Participants discontinuing from the primary treatment protocols for any reasons will be enrolled in this LTFU. This will allow collecting data on long-term safety and efficacy (as applicable) as mandated by the health authorities of all patients treated with CAR-T Therapy within the concept of a single protocol. 

Collection of such long-term effects of CAR T-cell therapy will help to further define the risk-benefit profil of CAR-T therapies.

Conditions

This trial is treating people with cancer who participated in a previous Novartis clinical trial for CAR T-Cell therapy